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In the fight against breast cancer, the totality of tumour treatment dictated 
therapy outcome and the probability of cancer remission.  Differential 
metabolism of docetaxel (DCL) and tamoxifen (TAM), which resulted in drug 
antagonistic effects were shown to suppress treatment efficacy in 
subpopulation of cancer cells. However the potential of nanoparticles, which 
spatially protected both drugs from metabolizing enzymes to reduce this 
antagonism, remained to be elucidated. In this Biomaterials paper, we 
demonstrated that after the co-delivery of DCL and TAM in poly (lactide)-D-
α-tocopheryl polyethylene glycol succinate nanoparticles (PLA-TPGS NPs), 
drug antagonism was significantly reduced versus its free unprotected form, 
and this effect attenuated at high drug concentrations. The fluorescent model 
drug coumarin 6 encapsulated in nanoparticles, exhibited enhanced cellular 
uptake over its free counterpart, and surprisingly, at correspondingly low drug 
concentrations. Thus our data suggested that reducing drug antagonism was 
correlated to the cellular uptake of nanoparticles, resulting from the spatial 
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1.1.  PROBLEM STATEMENT 
Breast cancer affected more than 1.3 million women worldwide, killed about 
half a million women in the United States alone and had been the most 
prevalent cancer diagnosed for women each year [1,2]. While most drug 
combinations were synergistic, certain drug combinations were actually 
antagonistic [3]. Due to high tumour heterogeneity, chemotherapy involved 
more than a single drug administered at the same period, drug antagonism 
increased the drug dosage required for maximal anti-tumour efficacy, which 
escalated the toxicity to normal cells and could produce undesirable side 
effects. In this Biomaterials paper, we demonstrated that drug antagonism 
might be reduced by the spatial protection of anti-cancer drugs with 
nanoparticle, which suggested its great potential in anti-cancer applications [4].    
 
1.2.  RATIONALE FOR THE MULTIMODAL TREATMENT OF 
CANCER 
1.2.1. THE MECHANISM OF CANCER CELL PROLIFERATION   
The ability to perform unregulated cell growth during cell division was a 
recognized motif in human cancer [5]. Normal cells were able to initiate 
mitotic catastrophe in response to DNA damage, abnormal spindle formation 
and deficient checkpoint control mechanisms [6]. In contrast, cancer cells 
were less able to initiate mitotic catastrophe [7,8]. This was because cancer 
cells had altered genomes that overexpressed pro-survival proteins and 
dysfunctional transcriptional processes. Bcl-2, Bfl-1/A1, NF- κ B, TNFα, 
MUC1 and HECTD3 E3 ubiquitin ligase had been implicated in cancer 
proliferation [9–14]. In addition, estrogen signalling was found to regulate a 
large fraction of the transcriptome in a rapid, robust, and unexpectedly 
transient manner in cancer cells [15–17].  
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Estrogen receptors might regulate transcriptional processes in two ways 
[18,19]. First, estrogen binds to estrogen receptors in the nucleus; 
subsequently, these receptors form dimers and bind to estrogen response 
elements located in the promoters of target genes [20]. Second, estrogen 
receptors interacted with other DNA-binding transcription factors in the 
nucleus, without directly binding to DNA. The overexpression of estrogen 
receptors and estrogen signalling was associated with cancer cell proliferation 
[21,22]. 
 
Cells proliferated by division. During cell division, mitosis ensured that each 
daughter cell acquired a complete set of chromosomes [23]. Because 
centrosome orientation enabled proper chromosome segregation, microtubule 
was critically involved in cell division as it closely regulated the position of 
the centrosome with respect to intracellular components during mitosis [24,25]. 
There were different types of microtubules, each with their unique role. Astral 
microtubule tethered centrosome to actin cytoskeleton, which defined 
centrosome orientation with respect to intracellular component [24]. 
Kinetochore microtubule established functional interaction between 
chromosomes and centrosomes, which mediated the movement of 
chromosome [26]. Inter-polar microtubule connected adjacent centrosome, 
which created stability between adjacent centrosomes [27]. 
 
The understanding of these mechanisms of cell proliferation is critical. It 
enables researchers to develop, augment or use anti-cancer drugs to treat 




1.2.2. THE REDUCTION OF CANCER CELL PROLIFERATION 
 WITH DOCETAXEL AND TAMOXIFEN 
DCL is a microtubule stabilizing taxane that induced cell death through 
mitotic catastrophe [28]. Cells assembled dynamic sub units of microtubules 
during mitosis [29]. By stabilizing microtubules with DCL, mitosis becomes 
incomplete [30]. This arrested cell division, which led to cell death [31]. 
Because DCL attacked cancer cell by stabilizing microtubules, which was a 
fundamental cellular component common in proliferating cells, it had been 
widely used in treating breast, prostate, liver and gastric cancer [32–39]. TAM 
is an estrogen receptor antagonist, which regulated gene transcription 
responsible for cancer cell proliferation [40,41]. Because TAM binds to 
estrogen receptor, it blocked estrogen from binding to estrogen receptor, 
which would otherwise activate proliferative cell signalling. TAM had been 
used in the treatment of ER positive breast cancer and in the reduction of 
breast cancer risk [42–44].  
 
Side effects of DCL included acute toxicities such as hypersensitivity, 
hypotension, nausea and pain; it could also cause delayed toxicities such as 
myelosuppression, alopecia, peripheral neuropathy, rash and edema [45]. Side 
effects of TAM included endometrium hyperplasia and an increased risk of 
endometrial cancer, deep venous thrombosis, pulmonary embolism, cataract, 
ovarian cyst and ischemic stroke [46–51].  
 
However, all anti-cancer drugs had side effects, although it might vary in 
presence and degree with the type of drug [52].  Nausea and vomiting were 
common [53]. Myelosuppression weakened the immune system, which linked 
to infection [54]. Thrombocytopenia predisposed to bleeding [55,56]. 
Anaemia was associated with chronic obstructive pulmonary disease and 
atherosclerotic cardiovascular disease [57,58]. Hair loss (alopecia) was a 
common trait of patients undergoing chemotherapy [59].  
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Although in general, the mechanism of action of the drug, drug dose, genetic 
signature of the tumour cells and cellular resistance mechanisms could 
influence the anti-cancer drug response, these side effects might be managed 
more effectively with a formulation capable of exhibiting high therapeutic 
effect at low dose. In addition, the heterogeneity of the tumour had an impact 
on the anti-cancer drug response. 
 
1.2.3. THE COMPLEXITY OF TUMOUR ENVIRONMENT 
First, cancer is an overly simplified word to describe a complex disease; It 
differed in each patient and the disease unceasingly advanced ever more 
complex into an interplay of diverse cell populations [60]. Second, cancer is a 
process of clonal evolution; It resulted in tumours with diverse genetic and 
molecular alterations [61]. In addition, many factors had been implicated in 
cancer progression: inflammatory stimuli, the immune response, mechanical 
stresses, therapeutic intervention, diet and micro biota [62–68]. Together, 
these factors impacted which subpopulation of cancer cells survived, 
proliferated, spread and resisted treatment. Therefore, multimodality treatment 
is a logical solution to tackle a multi-faceted problem such as cancer. 
 
1.2.4. THE EVASION OF DRUG RESISTANCE 
Intrinsic resistance is the phenomenon of ineffective therapy prior to receiving 
treatment due to the pre-existence of certain resistance mediating factors in the 
cell. Acquired drug resistance occurred when cancer cells that were initially 
sensitive to treatment, gained resistance during the treatment, which was 
caused by mutations and adaptive responses of the cancer cell via the 
activation of compensatory signalling pathway [69]. Tumours commonly 
acquired drug resistance in the course of treatment [70]; multidrug resistance 
had been a major cause of failure in chemotherapy [68]. Drug resistance could 
arise due to pharmacokinetic resistance as a result of low drug concentration in 
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tumour cells, kinetic resistance due to an inefficiently small subgroup of the 
cell population in a susceptible state, and mutations that produced biochemical 
resistance in the tumour cells to the drug [71]. These factors could be 
especially magnified in highly heterogeneous tumour because it contained 
different sub-groups of cell that exhibited differential cellular uptake of anti-
cancer drug, possessed varying types of intrinsic resistance and responded 
differently to a given mutagenic agent.  
 
One notable cause of drug resistance was caused by the presence of 
permeability glycoprotein (P-gp) on cell membrane, which  pumped out drug 
molecules from inside the cell by an adenosine tri-phosphate (ATP) dependent 
mechanism [72]. The evasion of P-gp efflux could improve area under curve 
(AUC: graph of drug concentration over time) and hence increased the 
therapeutic effect of anti-cancer drugs. Nanoparticles (NPs) had been 
delivered with TPGS in order to bypass P-gp efflux [73].  TPGS was found to 
modulate P-gp efflux transport via P-gp ATPase inhibition. Although the exact 
inhibition mechanism remained unknown, what was known on TPGS is that it 
is neither a P-gp substrate nor a competitive inhibitor in P-gp substrate efflux 
transport [74].  
 
1.2.5. THE SUPPRESSION OF HETEROGENEOUS TUMOURS 
WITH MULTIMODAL THERAPY 
Breast tumours were highly heterogeneous in its genetics and this was 
correlated with the volume of poorly differentiated cancer cells [75,76]. 
Treatment became less effective because subpopulation of drug resistant cells 
repopulated the tumour after the first round of therapy [77–80]. This was 
because heterogeneous tumours responded poorly to treatment using a single 
drug and was especially so when a drug ‘killed’ via a highly selective pathway. 
For example, the drug Herceptin was commonly used in treating human 
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epidermal receptor 2 (HER2) overexpressed cells, but did not work well on the 
triple negative phenotype [81,82]. Hence, the sole administration of Herceptin 
could not fully treat tumours with subpopulation of cells not expressing HER2. 
To combat the heterogeneous tumour, multimodal treatment such as 
combination drugs were administered clinically. For example, anastrozole-
fulvestrant and cyclophosphamide- methotrexate-fluorouracil had been 
combined in treating metastatic breast cancer and radical mastectomy 
respectively [83,84].  
 
1.2.6.  THE PROMOTION OF DRUG SYNERGISTIC EFFECTS WITH 
MULTIMODAL THERAPY 
Synergistic combinations could increase cytotoxic effects that exceeded the 
summation of treatment effect of the individual agent [85]. For example, the 
combination of DCL and TAM were shown to be synergistic in triple negative 
breast cancer cell line [86]. Drug absorption, distribution, metabolism and 
excretion might be altered by adding another drug that enhanced overall 
therapy in two ways: minimising dose related side effects, while having equal 
or an even higher level of efficacy; diminished or deferred attainment of drug 
resistance [87,88]. There are 3 main pharmacodynamics mechanisms. Anti-
counteractive: the action of drug that decreased the molecular pathway’s 
counteractive behaviour to repel a drug’s therapeutic effect. Complementary: 
the action of drug that involved a positive modulation of a target or process by 
approaching the pathway at different points. Facilitating: the enhancement of 
drug activity by one drug on the other [89]. 
 
There are different classes of therapeutic agents that might be combined 
synergistically; synergistic effect might occur between any random 
combination of molecular drug, protein, lipid, RNA therapeutic and 
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nanoparticle. Lipid-molecular drug: sphingosine-1-phosphate—a sphingolipid 
metabolite—was synergistic with various chemotherapeutic molecular drugs 
such as docetaxel, doxorubicin and cyclophosphamide [90]. Nanoparticle-
molecular drug: nanoparticles of Fe3O4 was synergistic with gambogic acid on 
the apoptosis of K562 leukemia cells [91]. Protein-molecular drug: 
trastuzumab—a humanized anti-HER2 antibody—was synergistic when 
combined individually with carboplatin, docetaxel, vinorelbine and 4-
hydroxycyclophamide [92].  RNA therapeutic-molecular drug: polo-like 
kinase 1 siRNA was synergistic with docetaxel [93].  
 
1.2.7.  THE LIMITATION OF MULTIMODAL TREATMENT IS 
DRUG ANTAGONISM 
Subpopulations of cells within the tumour could have a diversity of responses 
to the same combination therapy. First, DCL and interferon-beta had 
antagonistic and synergistic effect when applied respectively on MCF7 and 
MDA-MB-231 cell lines [94]. Second,  it had been shown that the same 
combination of DCL and TAM could have antagonistic and synergistic effects 
respectively on estrogen receptor positive MCF7 and triple negative breast 
cancer cell lines [86,95]. Therefore, this suggested the outcome of DCL and 
TAM combination therapy depended also on cancer cell types within a 
complicated heterogeneous tumour tissue. Further aggravating the situation 
was the type of drug interaction was reported to be sensitive to the drug ratio 
used in the combination therapy [96,97]. These observations suggested that we 
might have reached a threshold in treating heterogeneous breast cancer [4].
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1.3.  THE REDUCTION OF DRUG ANTAGONISM WITH 
NANOPARTICULATE DRUG DELIVERY SYSTEM  
Nanoparticles that co-deliver therapeutic agents in combination and in pre-
determined drug ratios had been intensively studied for anti-cancer 
applications for many reasons [98]. Nanoparticles came in many forms and 
strategies but generally were able to carry multiple therapeutic agents, had 
appropriate sizes (100-200 nm) and surface coating (TPGS or poly ethylene 
glycol) to prolong systemic circulation (before reaching target site) and 
crossing of endothelial barriers at targeted sites, exhibited sustained 
therapeutic effects intracellular [99–107]. It ensured that a single cell received 
a mixture of therapeutic agents, which otherwise could be restricted due to the 
differential cellular uptake of the individual agents. These carrier-dependent 
qualities were valid regardless of drug combination and hence should increase 
the therapeutic effects in subpopulations affected by the bane of sub-optimal 
drug antagonisms [4]. 
 
There were different types of nanoparticles encapsulating DCL and TAM, 
either individually or in combination with other anti-cancer agents [108–111]. 
Synergistic effects among the therapeutic agents were studied relatively 
extensively versus antagonistic effects. The combination of TAM with either 
melphalan or fluorouracil were antagonistic [112]. Similarly, DCL was 
combined antagonistically with interferon-beta [94]. On the other hand,  DCL 
was synergistically combined with magnetic iron oxide for imaging and 
hyperthermia therapy, lacto bionic and folate acid for targeting, small 
interfering RNA and plasmid DNA for biological therapy [113–117]. Likewise, 
TAM was combined with transferrin and quercetin for synergistic cytotoxic 
effects [118,119]. But, much less was known about the role of nanoparticles in 
reducing drug antagonism that was vital for the overall therapy of 
heterogeneous tumour [4].  
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1.3.1. THE SPATIAL PROTECTION OF ANTI-CANCER DRUGS 
AGAINST METABOLIZING ENZYMES WITH 
NANOPARTICLES 
One drug could change the metabolism of the other drug and thus resulted in 
drug antagonism [85]; metabolism in turn, could be a major source of 
pharmacokinetic variability [120]. Drug metabolism occurred primarily in the 
liver and kidney [121,122]. Because chemotherapeutic drugs might lose 
activity upon metabolism, the evasion of metabolizing enzymes and the 
delivery of drugs to the cancer cells became essential. Nanoparticle drug 
delivery system might be applied for the following reasons [123]. First, 
nanoparticles could enhance the delivery of drugs to cancer cells by reducing 
drug loss to the liver and kidney [124–126]. Second, nanoparticles increased 
cellular uptake of drugs in cancer cells [4,73,127]. Third, it offered spatial 
protection of anti-cancer drugs against metabolizing enzymes intracellular of 
cancer cells [4].  
 
In the liver, the highest expressed CYP enzymes were CYPs 3A4, 2C9, 2C8, 
2E1, and 1A2; 2A6, 2D6, 2B6, 2C19 and 3A5 were less plentiful in the liver. 
CYPs 2J2, 1A1, and 1B1 were mainly expressed outside of the liver [128]. 
Cancer cells could express intracellular metabolizing enzymes, but the 
expression of which enzyme was cell-specific [129]. For example, CYP1B1 
was expressed by MDA-MB-231, MDA-MB-157, BT-20, MCF7 and ZR-75-1 
[130]. In addition, the MCF7 breast cancer cell line expressed CYP3A4, which 
was a substrate for both DCL and TAM [131]. The co-delivery of DCL and 
TAM, which were metabolized by the CYP3A4 enzyme, could saturate the 
metabolic pathway—leading to incomplete drug disposition and potentially 
unfavourable clinical effects [132,133].  
 
DCL alone was a potent anti-mitotic agent [134,135]. By itself, TAM was an 
anti-estrogenic drug where its more active metabolite, 4-hydroxytamoxifen 
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binds to the estrogenic receptor of breast cancer cells and thus prevented 
estrogenic ligand from exerting its proliferative action [133,136,137]. 
Although CYP3A4 enzyme was commonly involved in metabolizing DCL and 
TAM individually, the resulting anti-tumour activity was distinctive for the 
respective metabolite. Significant reduction in cytotoxic property was 
observed when DCL was metabolized [138]. In contrast, TAM was a pro-drug 
that required CYP3A4 enzyme and could therefore occupy its reaction moiety 
[139,140]. We reasoned that if we could spatially present both TAM and DCL 
together to CYP3A4 enzyme, TAM might act as a drug decoy for CYP3A4 
enzyme, thus sparing DCL of metabolism to its less active metabolite [4]. We 
thus hypothesized that the encapsulation of DCL and TAM in NPs could 
reverse free form DCL TAM antagonism; sacrificing TAM to metabolism by 
CYP3A4 enzymes would spare DCL to exert an anti-mitotic effect and 
simultaneously transforming TAM into its active metabolite to add on an anti-
proliferative effect [4]. 
 
To experimentally show this interesting concept, we synthesized 
biodegradable polymeric nanoparticles of poly (lactide)-D-a-tocopheryl 
polyethylene glycol 1000 succinate as matrix material for the encapsulation of 
DCL and TAM, to investigate whether these two drugs in nanoparticles had 
reduced drug antagonism in MCF7 cell line [95]. Various formulations of 
dual-drug nanoparticles, denoted as DDNPs, containing different drug ratios 
of DCL and TAM were synthesized to meet the aim of this paper.  
 
Poly lactic acid (PLA) is a synthetic biodegradable polymer, which hydrolysed 
into nontoxic hydroxyl-carboxylic acid through ester bond cleavage and then 
was metabolized into water and carbon dioxide through the citric acid cycle 
[142]. Because of its desirable biodegradability, low immunity and good 
mechanical strength, PLA had been approved for application in tissue 
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engineering, medical materials, drug carriers by the US Food and Drug 
Administration [143]. However, due to its weak hydrophilicity, PLA had 
excessively long degradation time and low drug loading of polar drugs [144]. 
TPGS contained polyethylene glycol, which had many advantages such as 
good hydrophobicity, flexibility, stealth property against recognition by 
immune cells, biocompatibility and reduced opsonisation [145–149].  
 
By copolymerizing PLA with TPGS, the material properties of PLA could be 
improved. The PLA-TPGS copolymer had already been used to produce 
nanoparticles with good levels of drug encapsulation efficiency (EE), cellular 
adhesion, and desirable release rate [141]. The covalent tethering of TPGS to 
PLA prevented desorption of TPGS from the particle surface. This step 
improved EE and subsequently a more consistent drug release rate [141]. 
Additionally, TPGS inhibited P-glycoprotein mediated multi-drug resistance 
and had an intrinsic toxicity on cancer cells [150,151]. 
 
1.3.2. THE ELUSION OF DRUG SOLUBILITY RELATED SIDE 
EFFECTS WITH NANOPARTICLE 
DCL and TAM  had poor solubility in aqueous solutions [152–155]. In this 
Biomaterial paper, DCL and TAM were solubilized by encapsulating in PLA-
TPGS nanoparticles, which absolved key issues related to drug solubility. 
DCL was covalently conjugated to acetylated carboxymethylcellulose to make 
docetaxel-conjugate nanoparticles, loaded in solid lipid nanoparticles, and was 
developed preclinical and applied clinically [156–158]. Similarly, TAM was 
conjugated to gold nanoparticles, and loaded in solid lipid and polymeric 
nanoparticles [109,159,160]. Previously, Cremophor EL was used to enhance 
solubility of drugs for intravenous therapy [161]. Unfortunately, Cremophor 
EL caused multiple side effects such as anaphylactic hypersensitivity reactions, 
nephrotoxicity, neurotoxicity, and cardio toxicity [162]. Hence, efforts were 
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made to increase the solubility of hydrophobic therapeutic agents without 
using Cremophor EL.  
 
Solubilisation was enhanced through the uptake of hydrophobic drugs by 
complex formations with co-solvent or surfactant systems consisting of 
amphoteric compounds and ionic/non-ionic surfactants [163]. These methods 
comprised of co-solvents polysorbate 80/ethanol/pluronic L64, water-soluble 
polymers (e.g. polyethylene glycol and TPGS), emulsions, cyclodextrines and 
nanoparticle formulations [164]. These innovations were successful. 
Significant reduction in anaphylactic hypersensitivity was reported when DCL 
was solubilised in polysorbate 80 and ethanol compared to Cremophor EL 
[31]. Nanoparticle formulations made of poly (lactic-co-glycolic acid) were 
able to enhance drug solubility, provided sustained drug release and permitted 
surface functionalization [165–167].  
 
1.3.3. THE EVASION OF DOSE-RELATED SIDE EFFECTS BY THE 
MANIPULATION OF NANOPARTICLE SIZE, 
MORPHOLOGY AND SURFACE CHEMISTRY 
A long plasma half-life and low clearance from blood circulation increased the 
probability of PLA-TPGS nanoparticles to reach its intended target site and 
hence, decreased dose-related side effects. Opsonisation, which is the binding 
of serum proteins onto the surface of particles, was associated with the 
internalization of nanoparticles by the macrophages in the reticulo-endothelial 
system—mainly in the liver, spleen, lungs and bone marrow [168]. 
Opsonisation knocked nanoparticle off target [169]. The manipulation of 
particle size, zeta potential, surface morphology, deformability and 





Spherical particle below 100nm allowed for extravasation from leaky tumour 
vasculature. But, size needed to be bigger than 5 nm to escape glomerular 
filtration. The size of nanoparticles might be adjusted by experimentally 
determining component composition. Hydrophilic surfaces had longer 
circulation in blood [173]; the covalent attachment of polyethylene glycol or 
TPGS, on nanoparticle surface decreased surface hydrophobicity and 
opsonisation. This was found to increase circulation time [174,175].  
 
Viruses and bacteria were naturally occurring nano-complexes that had 
evolved into defined sizes, shapes and possess chemistries to mediate 
interactions with biological systems [176]. Similarly, the shape of nanoparticle 
could influence its uptake by cells [176,177]. Disc versus rod shaped 
nanoparticles had better cellular uptake in some mammalian cells [178]. HeLa 
cell line was able to internalize non-spherical micro particles by endocytosis; 
in addition rod-like particles exhibited high internalization rates—reminiscent 
of the advantageous cellular internalization of rod-like bacteria in non-
phagocytic cells [179]. Rod versus spherical nanoparticles exhibited higher 
accumulation at target sites in vivo [180].  
 
1.3.4. THE SUSTAINED RELEASE OF TAMOXIFEN AS A 
STRATEGIC DECOY WITH NANOPARTICLE 
TAM  needed to be released from the nanoparticles to act as a decoy for DCL 
[4]; a sustained release profile of TAM was preferred as it provided a 
consistent decoy. There were controlled release formulations of TAM 
derivatives. TAM citrate was loaded in lecithin/chitosan nanoparticles and 
guar gum nanoparticles exhibiting sustained release by the biodegradation of 
the carrier nanoparticle [181,182]. TAM was loaded in alginate-albumin 




Drug release profile might be controlled by varying the chemistry in 
nanoparticles [186]. An adequate concentration of intracellular drug 
concentration was needed to exert a therapeutic effect [187]. Efficacy of 
chemotherapy might be determined by the area under the curve of the time 
versus effective drug concentration measured in blood [188]. Sustained drug 
release was associated with drug diffusion and erosion, degradation, or 
swelling of the carrier material [71]. A known amount of drug was usually 
physically encapsulated in, covalently attached to or non-covalently associated 
with a carrier [189–191]. The choice of carrier was determined by analysing 
drug solubility, stability, drug-carrier interaction and drug physical properties 
[192]. For elaboration, the carrier was chosen such that the drug formed an 
attractive force with the carrier, remained stable during and after synthesis 
with regards to temperature and pH and not be converted to undesirable 
polymorphs, which might have lower solubility, during encapsulation, storage 
and/or release conditions [193].  
 
Carriers made of synthetic polyester such as poly lactic acid were of interest 
due to its biocompatibility and biodegradability properties [194,195]. On this 
note, poly (lactic-co-glycolic acid) had been approved by the federal drug 
administration for use in drug delivery [196]. However, drugs might form tight 
attractive forces with its carrier matrix, which resulted in incomplete drug 
release [197]. In contrast, poly (lactic acid) carrier was able to exhibit 
sustained drug release [198].  
 
1.3.5. THE REDUCTION OF SIDE EFFECTS BY TARGETING 
Cancer and normal cells such as bone marrow and intestinal epithelium cells 
with rapid turnovers, were both affected by anti-cancer drugs, which 
‘attacked’ without selectivity [71]. Since PLA-TPGS nanoparticles targeted 
cancer cells via passive targeting, nanoparticles could confer an extent of 
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selectivity in treating cancer. Moreover, the covalent attachment of targeting 
ligands at the surface of nanoparticles was an additional selectivity for the 
accumulation of nanoparticles in the tumour [199]. Preferential accumulation 
of anti-cancer drugs in tumour could increase therapy effects in tumour and 
minimize side effects in normal cells [200].  
 
Drug targeting by nanoparticle was controlled by physicochemical principles 
such as surface charge, hydrophobicity and ligand-receptor recognition 
[201,202]. There were two mechanisms of targeting: passive targeting took 
advantage of the enhanced permeation and retention effect in leaky vessels—
characteristic of tumour—which allowed nanoparticle to enter and 
accumulated in tumour [167]; active targeting made use of high affinity 
ligands, which bind to target receptors—overexpressed on the surface of 
cancer cells [203]. Affinity ligands used were based on ligand-receptor pair in 
cells. For example, folic acid binds to folate receptor while Herceptin binds to 
HER2 receptor. Nanoparticles were conjugated with Herceptin and folate acid 
in treating cancer cells, which overexpressed these cellular membrane 














2. MATERIALS AND METHODS 
2.1.   MATERIALS 
PLA-TPGS was synthesized via a ring-opening polymerization in accordance 
to previous publication [206]. Docetaxel (anhydrous, 99.56% purity) was 
purchased from Shanghai Jin he Bio-Technology Co. Ltd, China. Vitamin E 
TPGS (D-a-tocopheryl polyethylene glycol 1000 succinate, C33O5H54 
(CH2CH2O) 23) was bought from Eastman Chemical Company, USA. Succinic 
anhydride, 4-(Dimethyl amino) pyridine (DMAP), stannous octoate 
(Sn(OOCC7H15)2), Tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), 
coumarin-6, phosphate buffered saline (PBS, pH 7.4), 3-(4,5- dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, 
trypsinethylenediaminetetraacetic acid (EDTA), paraformaldehyde (PFA), 
dichloromethane (DCM) and lactide (3, 6-dimethyl-1, 4-dioxane-2, 5-dione, 
C6H8O4) were all from Sigma Aldrich (St. Louise, MO, USA). Ethanol was 
purchased from VWR Singapore Pte Ltd. Tween-80 was obtained from ICN 
Biomedical, Inc. (OH, USA). Triton X-100 was from USB Corporation (OH, 
USA). Fetal bovine serum (FBS), penicillin streptomycin solution, Alexa 
Fluor® 647 Phalloidin and Prolong® Gold Anti fade Reagent with DAPI were 
made available by Invitrogen. Dulbecco’s Modified Eagle’s Medium (DMEM) 
was obtained from Thermo Scientific Hyclone (South Logan, USA). MCF7 
breast cancer cells were obtained from American Type Culture Collection 
(ATCC). Ultrapure water was processed by the Milli-Q plus System 
(Millipore Corporation, Bedford, USA). 
 
2.2.  PREPARATION OF NANOPARTICLES 
The nanoparticles were prepared via the nanoprecipitation method [207]. 
Concisely, weighted amount of PLA-TPGS, DCL and TAM (drug to polymer 
weight ratio 1:10) were dissolved in THF with a final polymer concentration 
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of 10 mg/mL. The organic solution was added drop-wise using a 1mL syringe 
attached with a 21G needle, into ultrapure water at an organic to water volume 
ratio of 1:6 under rigorous stirring in room temperature. After 3 h, the solution 
was washed for 3 cycles in which 1 cycle of washing involved: centrifugation 
of nanoparticle solution at 15,000 rpm for 20 min in 4 °C; discard supernatant, 
add fresh ultrapure water to the pellet, re-suspension by vortex and sonication 
to obtain a homogeneous nanoparticle solution. After washing, the solution 
was then stored in 4°C. The same procedure was applied to synthesize the 
fluorescent C6 loaded nanoparticles denoted as C6 NPs, with drug completely 
replaced with C6. 
 
2.3.  CHARACTERIZATION OF NANOPARTICLES 
Nanoparticle size (Z-average) along with polydispersity, and zeta potential 
were measured by dynamic light scattering (DLS) and electrophoretic light 
scattering respectively (Zetasizer Nano ZS, Malvern Instruments Ltd, 
England). The samples were prepared by diluting the nanoparticle suspension 
with ultrapure water to a count rate of 200-400 kcps and sonicated for 5 min 
immediately before each measurement. Data expressed as mean ± standard 
deviation of triplicate measurements. 
 
DCL and TAM load were quantified by high performance liquid 
chromatography (HPLC, Agilent LC1100, Agilent, and Tokyo, Japan) at 
absorption wavelengths of 230 and 265 nm respectively with a UV/VIS 
detector. A reverse-phase column (Eclipse XDB-C18, 4.6 × 250 mm, 5 mm) 
was used. The mobile phase used for DCL and TAM were respectively 
acetonitrile/water (1:1 volume ratio) and methanol/water/triethylamine 
(89:11:0.11 volume ratio). In brief, nanoparticle solution was mixed by vortex 
and sonication to obtain homogeneous samples of 0.5mL each, freeze-dried 
and dissolved in DCM to free the encapsulated drugs from the polymer matrix. 
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After evaporating DCM in a vacuum oven, the dry sample was dissolved 
completely in 0.5mL of mobile phase by vortex and sonication. The samples 
were filtered by 0.45 μm PVDF membrane prior to HPLC analysis. Standard 
curve was obtained by first plotting the absorbance against known 
concentrations of DCL and TAM, followed by the insertion of a linear trend 
line—which was subsequently used to interpret the drug concentration in the 
samples. The standard curves were found to be linear with R2 = 0.99. Drug 
load was designed to be the weight of encapsulated drugs in μg divided by the 
total weight of the nanoparticles in mg. Hence, the unit of drug load was μg 
drug/ mg nanoparticles. Drug load expressed as mean ± standard deviation of 
triplicate measurements. 
 
Nanoparticle surface morphology was visualized by field emission scanning 
electron microscopy (FESEM, JSM-6700F, JEOL, and Japan) at 50,000 
magnification and an accelerating voltage of 5 kV. Samples were coated with 
platinum by JFC-1300 platinum coater (JEOL, Tokyo, Japan) for 30 s at 30 
mA prior to imaging. 
 
To study the in vitro drug release of nanoparticles, samples were dispersed in 
1 X PBS (pH 7.4) containing 0.1% v/v Tween-80, which functioned to 
increase the drug solubility of PBS so as to simulate the sink condition. 
Samples were placed in a rotating water bath at 37 °C and 90 rpm. At chosen 
time intervals, the tubes were centrifuged at 15,000 rpm for 20 min. The 
supernatant was collected and the pellet was re-suspended in fresh PBS to 
continue the drug release study. The same procedure for the quantification of 
drug load was applied to measure the drug released in the supernatant. 
 
For the in vitro colloidal stability study of nanoparticles, the nanoparticles 
were dispersed in 1 X PBS (pH 7.4) containing 10% FBS, which simulated the 
in vitro conditions of nanoparticles in DMEM. Similar to in vitro drug release, 
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samples were placed in a rotating water bath at 37 °C and 90 rpm. 
Nanoparticle solution were sampled at chosen time intervals and nanoparticle 
size were measured via the same procedure as mentioned previously. Data 
represent mean ± standard deviation of triplicate measurements. 
 
2.4.  IN VITRO CELLULAR UPTAKE AND CYTOTOXICITY     
STUDIES 
MCF7 breast cancer cells were cultured with Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% FBS and 1% penicillin-
streptomycin solution. Cells were cultured in cell culture flask and grown in 
an incubator at 37 °C and 5% carbon dioxide. Upon 70-90% cell confluence—
which was confirmed visually under a light microscope—the DMEM was 
extracted and rinsed twice with 10 mL 1 X PBS (sterilized) to remove all 
traces of serum, which would otherwise inhibit the suspension of adherent 
cells caused by Trypsin-EDTA. 4 mL of Trypsin-EDTA solution was added, 
incubated at 37°C for 5 min and observed under light microscope for cell 
dispersion. Incubate long times until cell dispersion may be observed. 6 mL of 
DMEM was added and the cell suspension was transferred to a tube for 
centrifuge at 1,500 rpm for 5 min. The supernatant was discarded and cell 
pellet was re-suspended in 6 mL DMEM. For subculture, 0.5 mL of cell 
suspension was added to culture flask for cell growth. For cell seeding, first 
perform 10 times dilution on 1 mL of cell suspension, cell count with 
haemocytometer (C-Chip), aliquot appropriate volumes of cell suspensions 
into cell plate and allow cell growth to confluence before subsequent use. 
 
To study both the qualitative and quantitative effects of nanoparticle on the 
cellular uptake of molecular drugs, medium was replaced by Coumarin 6 
loaded nanoparticle suspensions (C6 NP) or C6 free drugs at various C6 
concentrations. 3 sets of in vitro cellular uptake experiments were conducted. 
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C6 load was determined via the same procedure as drug load. The curve was 
found to be linear with R2 = 0.99. C6-NP and C6 were diluted with DMEM to 
obtain various concentrations. Confocal laser scanning microscopy was used 
in the qualitative study. Cells were seeded in an 8-well cover glass chamber 
(LAB-TEK, Nagle Nunc, IL, USA) at  cells/mL DMEM. At 
confluence, C6 and C6-NP at various concentrations were added into the cells 
and incubated for 2 h at 37ºC. The cells were rinsed thrice with 1 X PBS and 
fixed with 4% PFA for 15 min at 4°C. Thereafter, the cells were rinsed thrice 
and immersed in 1 X PBS—containing 0.2% (v/v) Triton X-100—for 5- 10 
minutes at room temperature. Subsequently, the cells were rinsed thrice, 
Phalloidin solution was added and left in room temperature for 20-30 min in 
the dark. The Phalloidin solution was extracted and the cells were rinsed thrice 
with PBS. With the chambers removed from the glass slide, add 6μl Prolong® 
Gold Anti-fade Reagent with DAPI to each well and mount slide cover on 
glass slide. Nail polish was applied at the edges of the slide cover to seal the 
slides and was left to dry. The sample was light sensitive and needed to be 
kept under aluminium foil at 4℃ prior to imaging. 
 
For quantitative study, cells were seeded in 96-well black plate (Costar, IL, 
and USA) at 5 × 104 cells/mL DMEM. After 0.5 and 2 h incubation, cells were 
rinsed thrice with PBS and immersed in 0.5% Triton X-100 in 0.2 mole/L 
sodium hydroxide solutions. After 15 min incubation under gentle shaking, the 
fluorescent intensities were measured with a micro plate reader at 430/485 nm 
(Excitation/Emission). Relative cellular uptake efficiency of C6 NP versus 







For the in vitro cellular cytotoxicity studies, cells were seeded in 96-well 
transparent plates (Costar, IL, and USA) at 5 ×104 cells/mL DMEM. 
Nanoparticles and free drugs were diluted in DMEM to produce varying 
concentrations of drug; UV irradiation was applied for 2h to sterilize the 
samples prior to the experiment. Upon confluence, the DMEM in the cells was 
replaced with nanoparticles suspensions or free drugs at various 
concentrations and incubated for 72 h. MTT assay standard protocol was 
adopted for cell viability measurements. 3 sets of in vitro cytotoxicity 
experiments were conducted. 
 
We evaluated the antagonistic effects between DCL and TAM by applying the 
, whereby  
and  represented the IC50 of drugs used in the combination 
treatment,  represented single drug IC50. An 
index lesser than 1 denotes drug synergism while larger than 1 was an  
antagonistic effect [208]. 
 
2.5. STATISTICAL ANALYSIS 
Two sample t-test was used to evaluate the significance of the 
therapeutic/uptake differences between free drugs and nanoparticle 
formulations. P<0.05 was chosen to determine the statistical significance of 








3.  CHARACTERIZATION OF DUAL-DRUG NANOPARTICLES 
(DDNPS) 
3.1.  PARTICLE SIZE AND SIZE DISTRIBUTION STUDIES 
Chemotherapy agent DCL and endocrine agent TAM were loaded into the 
PLA-TPGS polymeric matrix of the nanoparticles via the nanoprecipitation 
method (Fig. 1.1). Four formulations of dual drug loaded nanoparticles 
(DDNPs) were synthesized by varying the feeding ratio (by weight) of the two 
agents, DCL and TAM. The total drug amount was fixed to one tenth of the 
polymer weight and feeding ratio (DCL: TAM) and were respectively at 1:1, 
1:5, 1:10 and 1:15. The Z-average diameter (particle size) and polydispersity 
(PDI, size distribution) of the DDNPs were detailed (Table 1.1). Similar 
particle sizes were observed across the formulations of DDNPs, which ranged 
from 179.5 to 186.5 nm and that the polydispersity was less than 0.186, 
indicating a narrow size distribution. DCL and TAM load were measured by 
HPLC and subsequently employed to compute the resulting DCL versus TAM 
weight ratio. Dual drug loaded nanoparticle systems without drug conjugation 
to polymer matrix did not have precise ratio metric control over drug loading 
(Table 1.2 and 1.3) [209]. However, the outcome of combination therapy 
depended on the drug ratio. Hence in this study, to get some idea of the 
optimum drug ratio for maximum therapeutic effect, four formulations of 





Figure 1.1: Material and particle synthesis methods. (A) Synthesis 
reaction of PLA-TPGS. (B) Preparation of nanoparticles via the 
nanoprecipitation method.  
 
Table 1.1: Characterization of dual drug nanoparticles (DDNPs). Data 





Table 1.2: Characterization of experimentally repeated batch of dual 






Table 1.3: Characterization of single drug loaded and empty 




3.2.  PARTICLE MORPHOLOGY 
Visual confirmation of DDNP formation was observed by field emission 
scanning electron microscope (FESEM) (Fig 1.2). Nanoparticle solution at 2 
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and 0.02 mg nanoparticle/mL ultrapure water were tested to permit analysis of 
particle size and shape at different particle concentrations. DDNPs were 
spherical with smooth surface; size was below 200 nm with a narrow size 
distribution. This corroborated with the size and polydispersity measurements 
of DLS. Particle size and polydispersity at 2 mg/mL were larger than at 0.02 
mg/mL; multiple layers of nanoparticles at 2 mg/mL might have caused a 




Figure 1.2: Field emission scanning electron microscopy (FESEM) 
images of DDNPs taken at (A) 2 and (B) 0.02 mg nanoparticle/mL 










4. IN VITRO DRUG RELEASE AND COLLOIDAL STABILITY 
STUDIES  
4.1.  DDNPS EXHIBITED TIME-DEPENDENT, NON-
CONTINUOUS STEP-WISE MODE OF COLLOIDAL STABILITY 
The colloidal stability of DDNP was studied by measurement of the NP size, 
which was sampled over chosen time points within 120 h, for NPs suspended 
in PBS supplemented with 10% FBS at 37ºC and 90 rpm. The colloidal 
stability of the DDNPs in the presence of protein was tested by adding FBS. 
DDNPs exhibited a step-wise mode of decrease in colloidal stability, which 
was represented by a gradual increase in NP size (Fig. 2.1A). Nanoparticle 
size ranged from 248 to 274nm during the first 48 h. Thereafter, nanoparticle 
size increased—but was still within 326nm for the next 48 h— and finally 
reached 529nm at 120 h. Hence, we concluded that DDNPs had time 
dependent, non-continuous step-wise mode of colloidal stability [4]. Based on 
this data, DDNPs were able to maintain good colloidal stability when applied 
in vitro conducted within 72 h of incubation time. In addition, smaller sized 
nanoparticles observed in the first 48 h had a larger combined surface area, 
which could have supported the higher rate of drug release observed in the in 




Figure 2.1: In vitro colloidal stability and drug release. (A) Step-wise 
mode of reduction in colloidal stability of DDNPs. Colloidal stability of 
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DDNPs demonstrated by DLS measurement of NP diameter over 
chosen time points within 120 h in PBS, supplemented with 10% FBS 
at 37ºC and 90 rpm. Data represent mean ± SD, n = 3. In vitro drug 
release profile of (B) DCL and (C) TAM of the 4 formulations of DDNPs 
taken over chosen time points after incubation at 37ºC and 90 rpm. 
Data represented mean ± SD, n = 3. 
 
4.2.  RELEASE OF DRUGS IN PREDETERMINED RATIOS 
It could be seen from Fig. 2.1B and C that there was an initial burst release in 
the first 12 h, during which 17.57 ± 0.82% - 36.05 ± 0.50% DCL and 17.38 ± 
0.03% - 61.32 ± 0.04% TAM were released from the DDNPs. The burst 
release phenomenon was associated with drugs loaded near the surface of the 
nanoparticle [211]. In the following hours, DCL and TAM  were released from 
the nanoparticles in a sustained manner. After 120 h, the cumulative drug 
release profiles ranged from 28.52 ± 0.45% to 54.39 ± 0.44% and 25.32 ± 
0.03% to 71.65 ± 0.17% for DCL and TAM respectively. In general, 
DDNP33.6 and DDNP12.0 exhibited the largest and smallest drug release 
capacity respectively. In addition, because the drugs had similar solubility in 
PBS due to Tween80, DDNPs should be able to release combination drugs 
according to their initial loading ratio. This reduced unpredictability of drug 
proportions released in the already complicated drug interaction effects [4]. 
Thus DDNPs could offer this important advantage, because drug ratios could 
affect drug interaction in cancer cells, as shown in the following cytotoxicity 








5. IN VITRO CELLULAR UPTAKE AND CYTOTOXICITY OF 
DDNPS VERSUS FREE DRUGS 
5.1.  HIGHER THERAPEUTIC EFFECT OF DDNPS VERSUS FREE 
DRUGS 
We had employed the MCF7 breast cancer cell line—which had a known 
antagonistic effect towards combination of DCL and TAM—as an in vitro 
model of cancer to investigate the reduction of antagonistic effects of DCL 
and TAM, in DDNPs versus free drugs. The viability of the MCF7 cell line, 
incubated with each of the 4 formulation of DDNPs, at drug concentrations of 
1.5 -12μg/mL was systematically investigated in comparison with the viability 
of the MCF7 cell line treated with free drugs at the same drug concentrations. 
It could be observed that all formulations demonstrated dose dependent 
toxicity (Fig. 3.1A-D). In addition, the DDNPs showed superior in vitro 
therapeutic efficacy versus free drugs, especially at low drug concentration of 
1.5 – 3 μg/mL (p<0.01).  
 
It could be seen that the total drug IC50 of DDNPs was consistently lower 
versus free drugs across all 4 formulations (Fig. 3.1E and 3.2A) Also, the total 
drug IC50 at DCL: TAM of 1:0.5, 1:12.0, 1:25.6 and 1:33.6 were reduced by 
74.8%, 48.5%, 39.2% and 44.9% respectively, when co-delivered via DDNPs; 
this was an excellent advantage of DDNPs as it promoted higher therapeutic 
efficiency. Furthermore, total drug IC50 was observed to be lowest at DCL 
versus TAM of 1: 12.0 and 1: 25.6 for DDNPs and free drugs respectively 
(p<0.01). This suggested that TAM needed to be added in greater excess for 






Figure 3.1: Superior in vitro therapeutic efficiency of nanoparticle 
encapsulated drugs versus free drugs. (A-D) Nanoparticles improved 
the therapeutic efficiency of DCL-TAM combination therapy versus free 
drugs. MTT assay: MCF7 cell lines treated for 72 h with 4 formulations 
of DDNPs and tested against the respective free drug formulation at 
corresponding drug ratios and total drug concentrations. Data 
represented mean ± SEM (95% confidence interval), n = 6 and *p<0.01 
versus free drugs. (E) Comparative analysis of the therapeutic effect of 
DDNPs versus free drugs via total drug IC50, which was computed 
based on cell viability values. (F) Reduction in antagonistic effect of 
combination drugs when delivered in nanoparticles. Combination index 
calculated at total drug IC50. Results were mean ± SEM (95% 
confidence interval), n=6. *p<0.01 versus free drugs. (G-H) MTT assay: 
MCF7 cell line was treated for 72 h with single drug loaded 
nanoparticles (SDNPs). Data represented mean ± SEM (95% 
confidence interval), n = 6, *p<0.01, **p<0.05 versus free drugs. (I) 
Nano toxicity of PLA-TPGS carrier. PLA-TPGS concentration tested 
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correlated with average actual concentration of PLA-TPGS presented 
in DDNPs and SDNPs. Results were mean ± SEM (95% confidence 




Figure 3.2: (A) MTT assay: MCF7 cell line was treated for 72 h with 
free drug at DCL versus TAM ratio of 1:0.5. Data represented mean ± 
SEM (95% confidence interval) and n = 6.  (B) Comparative analysis of 
the therapeutic effect of SDNPs versus free drugs via drug IC50, which 
was computed based on cell viability values 
 
5.2.  DDNPS REDUCED DRUG ANTAGONISM 
The discouraging antagonism of two otherwise important drugs, DCL and 
TAM had therefore complicated the chemotherapy in breast cancer when these 
two drugs were in combination [95,212]. In our study, however, DDNPs could 
drive a wedge between these drug antagonism battles as we showed less 
antagonistic effects versus free drugs, which might be observed across all 4 
formulations [4]. In fact, one particular combination, DDNP12.0 even 
reversed the general free-dual drugs trend and boasted a mild but significant 
synergistic effect (Fig. 3.1F). The significant decrease in IC50 in MCF7 cell 
line showed that DDNPs had the potential to promote synergistic effects by 
reducing antagonistic effect [4]. The aforementioned conclusion was also 
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consistent for single drug loaded TAM nanoparticles, which demonstrated 
higher cytotoxicity compared to free drugs (p<0.01 and p<0.05) (Fig. 3.1G-H). 
However, the observed difference was not substantial compared to the effect 
achieved by DDNPs.  
 
In addition, single drug loaded DCL nanoparticles showed higher cytotoxicity 
than free drugs only at 12 μg/mL, with other concentrations not significantly 
different from free drugs (p<0.05 and p<0.5) (Fig. 3.2B). NP carrier showed 
some cytotoxicity when administered at polymer weight that corresponded to 
the polymer weight present in DDNPs—an advantage of using TPGS as a drug 
carrier (Fig. 3.1I). Since the effect of DDNP versus free drugs—which 
resulted in greater cytotoxicity versus free drugs—was prominent only when 
two drugs are encapsulated, this must had been achieved due to NP mediated 
drug interactions, i.e. NP reduced drug antagonism [4]. 
 
5.3.  NANOPARTICLE PLAYED A ROLE IN CELLULAR UPTAKE 
To investigate the role of nanoparticles in mediating the cellular uptake of 
drugs, coumarin 6 was used as a model drug because its fluorescence enabled 
easy quantitative and qualitative analysis. For a start, cellular uptake efficiency 
of C6 in MCF7 cell line after 2 h incubation was qualitatively evaluated using 
CLSM, and quantitatively measured by a micro plate reader. The green 
fluorescence represented C6, the blue fluorescence represented the nucleus 
and red fluorescence represented f-actin in the cytoplasm. The pictures were 
taken under the same excitation laser intensity. Green fluorescent laser 
intensity was adjusted to the maximum whereby no fluorescence may be 
observed in the control cells (without C6 or C6 NPs). Figure 3.3 showed the 
CLSM images of MCF7 cell line incubated with free C6 and C6 NPs at C6 
concentration of 3μg/mL. The images showed that C6 NPs were able to enter 
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the cell and were localized extensively in the cytoplasmic region. However, to 
examine whether free C6 had the same cellular uptake efficiency as C6-NPs, 
free C6 was added as a control. In comparison, free C6 was not significantly 
taken up by the cells. This suggested that nanoparticle played a role in 
mediating cellular uptake of C6 [4]. 
 
The uptake amount of DDNPs-C6 was also quantitatively determined by 
measuring C6- fluorescence. Figure 3.3D and E shows the relative cellular 
uptake efficiency of C6 NPs against free C6. After just a brief 30 mins of 
incubation, more C6 was internalized into MCF7 cell line for C6 NPs versus 
free C6 (p<0.01) at C6 concentrations of 1.5 – 6 μg/mL. However, C6 NP did 
not exhibit higher cellular uptake than free C6 at 12 μg/mL (p<0.4) probably 
due to the extremely high concentration gradient of free C6 that could also 
drive uptake of free C6 into the cell. After 2 h incubation, more C6 was 
internalized via C6 NPs relative to free C6 at concentration of 1.5 - 3 μg/mL 
(p<0.01), while no difference may be observed at 6-12 μg/mL (p<0.2 and 
p<0.4). These results indicated that NP mediated cellular uptake of C6 were 
both time and dose dependent [4]. This suggested that nanoparticles played a 
decreasing role in mediating cellular uptake as the drug concentration 
increased [4]. This was closely corroborated by cytotoxicity values in Fig. 3.1, 
which showed a declining advantage of DDNPs versus free drugs as the total 
drug concentration increased. In addition, the significant difference in cellular 
uptake of C6 NP versus free C6 only at low drug concentration might be due 
to the saturation kinetics of cellular uptake, which presupposed that cells 
might only take in substances up to a maximum limit [213]. That is to say, 
when drug concentrations were high, cells would have reached their maximum 
limit of uptake; nanoparticle mediated uptake was not able to increase this 
upper limit any further. Therefore, the effect of nanoparticle in mediating 






Figure 3.3: Nanoparticles enhanced cellular uptake of the model drug 
coumarin 6 into MCF7 cell lines. Qualitative study of cellular uptake by 
confocal laser scanning microscopy (CLSM) after 2 h incubation at 37 
ºC with (A) control well without C6, (B) 3 µg/mL of free coumarin 6 
versus (C) Coumarin 6 NPs. Bar represented 20µm. Quantitative study 
of cellular uptake by micro plate reader after (D) 0.5 and (E) 2 h 
incubation at 37 ºC at various C6 concentrations with free C6 versus 
C6 NPs. Bar graph data represented mean ± SEM (95% confidence 
interval), n = 6 and *p<0.01 versus free coumarin 6. 
 
However, such high concentrations of the therapeutic cargo is not going to be 
clinical relevant because the point of any pharmacological research is to 
reduce the dose and not to increase it. In addition, driving uptake of drugs 
purely through high concentration gradients is intuitively harmful to the cells 
due to potentially cell membrane damage and that can result in extensive 
necrosis which in turn causes collateral damage to the neighbouring normal 
cells. Instead, packaging in DDNPs capitalized on the endogenous endocytosis 
pathway to bring in the cargo and after endosomal release, would the positive 
effects of cells be controllably released.  
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Particles smaller than 8 nm would be subjected to renal clearance; dual drug 
loaded nanoparticles with size larger than 100 nm would elude hepatic 






















We applied a nanoparticle system formulating DCL and TAM for chemo- and 
endocrine therapy in nanoparticles of PLA-TPGS, which were denoted as 
DDNPs, for the treatment of cancer. It was shown that the DDNPs were able 
to reduce drug antagonism between DCL and TAM by spatially separating the 
metabolism of both drugs from the metabolic enzyme until the nanoparticle-
drugs construct reached the target cell. Considering that drug ratio had an 
effect on drug interaction, we demonstrated that this reduction in antagonism 
was consistent in all 4 formulations, with each presenting a different drug ratio. 
Next, we validated that the enhanced cellular uptake of drugs delivered by 
NPs explained further the role of NP in reducing drug antagonism. The uptake 
data also showed that the encapsulated drugs would be sufficiently protected 
from the drug metabolizing enzymes and the construct was intact. We 
concluded that our concept in protecting drugs from metabolism in the form of 
DDNPs have the potential to effect a tremendous improvement in the overall 
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